Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Elizabeth Plimack

Email
Center AffiliationsCancer Epigenetics

Publications (101) (print view)

no pagination
Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract. 2016 Jun 21;12(7):e755-64.   PMCID: PMC5015446
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.
Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)- tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016 Jul;27(7):1304-11.
O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 Dec;14(6):511-7.   PMCID: PMC5018246
Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016 Sep 20;34(27):3346-8.   PMCID: PMC5379635
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2016 Dec;68(6):959-67.
Plimack ER, Geynisman DM. Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. J Clin Oncol. 2016 May 09;34(18):2088-92.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1317-24.
Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Rathmell WK, Wood CG, Tannir NM. Management and Outcomes of Patients with Renal Medullary Carcinoma: A Multi-Center Collaborative Study. BJU international. 2016 Nov 08;.
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.
Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016 Jun;8(7):785-98.
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology (Williston Park). 2016 Feb;30(2):160-2, 176.
Zibelman M, Ramamurthy C, Plimack ER. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. Urol Oncol. 2016 Dec;34(12):538-47.
Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Current oncology reports. 2015 Dec;17(12):58.
Beard CJ, Gupta S, Motzer RJ, O'Donnell EK, Plimack ER, Margolin KA, Ryan CJ, Sheinfeld J, Feldman DR. Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. J Natl Compr Canc Netw. 2015 Jun;13(6):811-22.
Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU international. 2015 Sep;116(3):351-7.
Geynisman DM, Ross EA, Plimack ER. Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events?. Eur Urol. 2015 Jun 23;68(4):578-80.   PMCID: NA Editorial
Geynisman DM, Szmulewitz RZ, Plimack ER. Corticosteroids and prostate cancer: Friend or foe? [Comment; Editorial]. European Urology. 2015 Jan;67(5):874-5.   PMCID: NA Editorial
Knollman H, Godwin JL, Jain RI, Wong YN, Plimack ER, Geynisman DM. Muscle-invasive urothelial bladder cancer: An update on systemic therapy. Therapeutic Advances in Urology. 2015 Jan;7(6):312-30.   PMCID: 4647143
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Elizabeth Plimack Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Friday, February 02, 2018